Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
下载
收藏
页数:4
相关论文
共 50 条
  • [31] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis
    Siesto, Gabriele
    Cavina, Raffaele
    Romano, Fabrizio
    Vitobello, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 280 - 285
  • [32] The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery
    Bizzarri, Nicolo
    Marchetti, Claudia
    Conte, Carmine
    Loverro, Matteo
    Giudice, Maria Teresa
    Quagliozzi, Lorena
    Distefano, Mariagrazia
    Chiantera, Vito
    Scambia, Giovanni
    Fagotti, Anna
    GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 453 - 458
  • [33] MINIMALLY INVASIVE VERSUS OPEN INTERVAL DEBULKING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY FOR OVARIAN CANCER
    Margul, D.
    Seagle, B. L.
    Yang, J.
    Ann, P.
    Alexander, A.
    Kocherginsky, M.
    Shahabi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 760 - 760
  • [34] Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Trope, Claes G.
    Elstrand, Mari B.
    Sandstad, Berit
    Davidson, Ben
    Oksefjell, Halldis
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2146 - 2154
  • [35] Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Rios-Doria, E.
    Pezzillo, M.
    Ulm, M. A.
    Tillmanns, T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 127 - 128
  • [36] A comparison of postoperative morbidity in open versus robotic-assisted interval debulking surgery for epithelial ovarian cancer patients following neoadjuvant chemotherapy
    Zhang, Y.
    Staley, A.
    Tucker, K.
    Paraghamian, S. E.
    Wang, M.
    Clark, L. H.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 138 - 138
  • [37] Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery
    Pepin, K. J.
    Davis, M. R.
    Bregar, A. J.
    Melamed, A.
    Hinchcliff, E. M.
    Gockley, A. A.
    del Carmen, M. G.
    Horowitz, N. S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 140 - 140
  • [38] Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery
    Pepin, Kristen
    Bregar, Amy
    Davis, Michelle
    Melamed, Alexander
    Hinchcliff, Emily
    Gockley, Allison
    Horowitz, Neil
    del Carmen, Marcela G.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 612 - 616
  • [39] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
  • [40] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Shelly M. Seward
    Ira Winer
    Cancer and Metastasis Reviews, 2015, 34 : 5 - 10